Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer - Archive ouverte HAL Access content directly
Journal Articles Journal of Nuclear Medicine Year : 2020

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer

(1) , (2, 3) , (4, 5) , (4, 5) , (4, 6) , (1, 7, 4) , (4, 8) , (9) , (10) , (11, 4, 12) , (8) , (5) , (6) , (5, 12) , (4, 11) , (13) , (14) , (3) , (15, 16) , (1, 5)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Caroline Rousseau
  • Function : Author
  • PersonId : 938699

Abstract

Purpose: This prospective study evaluated the imaging performance of a novel immunological pretargeting positron-emission tomorgraphy (immuno-PET) method in patients with HER2-negative, carcinoembryonic antigen (CEA)-positive, metastatic breast cancer (BC), compared to computed tomography (CT), bone magnetic resonance imaging (MRI), and 18Fluorodeoxyglucose PET (FDG-PET). Patients and Methods: Twenty-three patients underwent whole-body immuno-PET after injection of 150 MBq 68Ga-IMP288, a histamine-succinyl-glycine peptide given following initial targeting of a trivalent anti-CEA, bispecific, anti-peptide antibody. The gold standards were histology and imaging follow-up. Tumor standard uptake values (SUVmax and SUVmean) were measured, and tumor burden analyzed using Total Tumor Volume (TTV) and Total Lesion Activity (TLA). Results: Total lesion sensitivity of immuno-PET and FDG-PET was 94.7% (1116/1178) and 89.6% (1056/1178), respectively. Immuno-PET had a somewhat higher sensitivity than CT and FDG-PET in lymph nodes (92.4% vs 69.7% and 89.4%, respectively) and liver metastases (97.3% vs 92.1% and 94.8%, respectively), whereas sensitivity was lower for lung metastases (48.3% vs 100% and 75.9%, respectively). Immuno-PET showed higher sensitivity than MRI and FDG-PET for bone lesions (95.8% vs 90.7% and 89.3%, respectively). In contrast to FDG-PET, immuno-PET disclosed brain metastases. Despite equivalent tumor SUVmax, SUVmean, and TTV, TLA was significantly higher with immuno-PET compared to FDG PET (P = 0.009). Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive, metastatic BC patients, and warrants further research.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02512957 , version 1 (20-03-2020)

Identifiers

Cite

Caroline Rousseau, David M Goldenberg, Mathilde Colombié, Jean-Charles Sébille, Philippe Meingan, et al.. Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer. Journal of Nuclear Medicine, 2020, pp.jnumed.119.236000. ⟨10.2967/jnumed.119.236000⟩. ⟨inserm-02512957⟩
80 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More